3rd Quarter - Report
BALLARD PARTNERS for NOVO NORDISK INC.
Firm
Client
Income
$120,000
Expenses
—
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Pharmacy PHA
Guidance regarding pharmaceutical regulations.
Foreign entity interest: Novo Nordisk A/S, Novo Holdings A/S, and Novo Nordisk Fondation, as parent companies of Novo Nordisk Inc., identified on the LD-1 report, have indirect interests in the issues identified in this report.
| Lobbyist | Covered position, as disclosed |
|---|---|
| BRIAN BALLARD | — |
| THOMAS BOODRY New | Intern, Sen.Bill Cassidy, Sept2017-Jan2021; LA, Sen.Marco Rubio, Jan2018-Jan2021; LD, Rep.Tony Gonzales, Jan2021-Nov2022; LD, Rep.Mike Waltz Nov2022-Jan2025;Spec.Asst. to President Donald Trump & Sen.Dir. for Leg. Affairs, WH,NSC,Jan2025-April2025 |
| SYLVESTER LUKIS | — |
| MONICA RODRIGUEZ | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.